Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Amgen's Maridebart Cafraglutide?
Maridebart Cafraglutide is a fusion protein commercialized by Amgen, with a leading Phase II program in Type 2 Diabetes. According...
Data Insights
Risk adjusted net present value: What is the current valuation of Amgen's Maridebart Cafraglutide?
Maridebart Cafraglutide is a fusion protein commercialized by Amgen, with a leading Phase II program in Type 2 Diabetes. According...